Skip navigation

About MorphoSys MorphoSys (FSE – NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional innovative therapies for patients with serious illnesses. The focus is on cancer. MorphoSys has developed with its partners through its leading expertise in antibody, protein and peptide technologies and has contributed to the development of more than 100 candidates, 28 of whom are currently in clinical development. In 2017, Tremfya (R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys antibody technology to obtain regulatory approval. Tafasitamab (MOR208), the company`s most advanced proprietary candidate, has been named after the U.S. FDA for a revolutionary treatment for the treatment of patients with relapsed/refractory lymphatic lymphoma (DLBCL). The MorphoSys Group, headquartered near Munich, employs approximately 405 people, including the Munich-based U.S. subsidiary MorphoSys US Inc. For more information, see www.morphosys.com. Investor Contact: Dr. Julia Neugebauer Director Tel:49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Christine Chiou Senior Director, Investor Relations Tel: `1 302 274 4773 cchiou@incyte.com Catalina Loveman Executive Director, Public Affairs Tel: `1 302 498 6171cloveman@incyte.com Dr. Booth, Dr.

Michael Division, Vice President Investor Relations – Corporate Responsibility Tel: $1,302,498 5914mbooth@incyte.com MorphoSys receives a $750 million down payment under the agreement and, in addition, upon signing the contract, Incyte will benefit from a $150 million interest in Morphosys` new U.S. stock price deposits. Depending on the achievement of certain development, regulatory and commercial milestones, MorphoSys may receive up to $1.1 billion in milestone payments. MorphoSys also receives staggered royalties for former U.S. companies. Tafasitamab`s net sales in the mid-10s to 200s were net sales. A live webcast is available in www.morphosys.com and on investor.incyte.com. Sophie Petersen Senior Specialist Tel: (0)89 / 899 27 26033 sophie.petersen@morphosys.com Based near Munich in Germany, the MorphoSys Group, including the full-fledged US subsidiary, MorphoSys INC., employs 500 people. For more information, see www.morphosys.com or www.morphosys-us.com. MorphoSys AG (FSE: MOR; standard premium segment; MDAX – TecDAX; NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) announced today that the companies have entered into a cooperation and licensing agreement for the development and marketing of the anti-CD19 tafasitamab (MOR208) that owns Morphosys.